1-[(Ethoxyamino)methyl]-2-sulfanylidenepyrimidin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-[(Ethoxyamino)methyl]-2-sulfanylidenepyrimidin-4-one
• 英文别名: 1-[(ethoxyamino)methyl]-2-sulfanylidenepyrimidin-4-one
• 化学式: C₇H₁₁N₃O₂S
• 分子量: 201.25
• InChiKey: XXPWHKHXZOQYCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  85.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• ACTIVATING JAK KINASE BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT INHIBITOR RESPONSE
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP3149207A2

  公开（公告）日：2017-04-05
• PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS
  申请人：LIFE TECHNOLOGIES CORPORATION

  公开号：US20160108466A1

  公开（公告）日：2016-04-21

  The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR.
• METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
  申请人：Flagship Pioneering, Inc.

  公开号：US20180179525A1

  公开（公告）日：2018-06-28

  The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.
• PROTEINS COMPRISING HLA-G ANTIGEN BINDING DOMAINS AND THEIR USES
  申请人：Janssen Biotech, Inc.

  公开号：US20220033505A1

  公开（公告）日：2022-02-03

  The invention provides antigen binding domains that bind human leukocyte antigen G (HLA-G) protein comprising the antigen binding domains that bind HLA-G, polynucleotides encoding them, vectors, host cells, methods of making and using them.
• [EN] ACTIVATING JAK KINASE BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT INHIBITOR RESPONSE<br/>[FR] ACTIVATION DE BIOMARQUEURS DE LA JAK PRÉDICTIFS DE RÉPONSE À UN ANTI-CORPS INHIBITEUR DE POINT DE CONTRÔLE IMMUNITAIRE
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2015184061A2

  公开（公告）日：2015-12-03

  The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.